Article cité par

La fonctionnalité Article cité par… liste les citations d'un article. Ces citations proviennent de la base de données des articles de EDP Sciences, ainsi que des bases de données d'autres éditeurs participant au programme CrossRef Cited-by Linking Program. Vous pouvez définir une alerte courriel pour être prévenu de la parution d'un nouvel article citant " cet article (voir sur la page du résumé de l'article le menu à droite).

Article cité :

Enhancing cognition through pharmacological and environmental interventions: Examples from preclinical models of neurodevelopmental disorders

Lorenzo Morè, Julie C. Lauterborn, Francesco Papaleo and Riccardo Brambilla
Neuroscience & Biobehavioral Reviews 110 28 (2020)

Dual-acting agents for improving cognition and real-world function in Alzheimer’s disease: Focus on 5-HT6 and D3 receptors as hubs

Mark J. Millan, Anne Dekeyne, Alain Gobert, Mauricette Brocco, Clotilde Mannoury la Cour, Jean-Claude Ortuno, David Watson and Kevin C.F. Fone
Neuropharmacology 177 108099 (2020)

Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT6 receptor ligands with significant selectivity for D3 over D2 receptors

Oscar M. Saavedra, Delphine Karila, Dominique Brossard, et al.
Bioorganic & Medicinal Chemistry 25 (1) 38 (2017)

Targeting the dopamine D3 receptor: an overview of drug design strategies

Antoni Cortés, Estefanía Moreno, Mar Rodríguez-Ruiz, Enric I. Canela and Vicent Casadó
Expert Opinion on Drug Discovery 11 (7) 641 (2016)

The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets

Manato Kotani, Takeshi Enomoto, Takeshi Murai, et al.
Behavioural Brain Research 305 212 (2016)

The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders

Mark J Millan, Jean-Michel Rivet and Alain Gobert
Journal of Psychopharmacology 30 (11) 1099 (2016)

Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases

Samuele Maramai, Sandra Gemma, Simone Brogi, et al.
Frontiers in Neuroscience 10 (2016)

The dopamine D 3 -preferring D 2 /D 3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia

David J.G. Watson, Madeleine V. King, Istvan Gyertyán, et al.
European Neuropsychopharmacology 26 (2) 208 (2016)

Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation

Roberto Maggio, Marco Scarselli, Marta Capannolo and Mark J. Millan
European Neuropsychopharmacology 25 (9) 1470 (2015)

On ‘polypharmacy’ and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal

Mark J. Millan
The International Journal of Neuropsychopharmacology 17 (07) 1009 (2014)

Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment

Mark J. Millan, Kevin Fone, Thomas Steckler and William P. Horan
European Neuropsychopharmacology 24 (5) 645 (2014)

The potential role of dopamine D3 receptor neurotransmission in cognition

Shinichiro Nakajima, Philip Gerretsen, Hiroyoshi Takeuchi, et al.
European Neuropsychopharmacology 23 (8) 799 (2013)

Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: The CNTRICS initiative

Mark J. Millan and Karen L. Bales
Neuroscience & Biobehavioral Reviews 37 (9) 2166 (2013)

Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia

Gerhard Gross, Karsten Wicke and Karla U. Drescher
Naunyn-Schmiedeberg's Archives of Pharmacology 386 (2) 155 (2013)

In Vivo Occupancy of Dopamine D3 Receptors by Antagonists Produces Neurochemical and Behavioral Effects of Potential Relevance to Attention-Deficit–Hyperactivity Disorder

V. Barth, A. B. Need, E. T. Tzavara, et al.
Journal of Pharmacology and Experimental Therapeutics 344 (2) 501 (2013)

Transient and rapid activation of Akt/GSK‐3β and mTORC1 signaling by D3 dopamine receptor stimulation in dorsal striatum and nucleus accumbens

Marie‐Josèphe Salles, Denis Hervé, Jean‐Michel Rivet, Sophie Longueville, Mark J. Millan, Jean–Antoine Girault and Clotilde Mannoury la Cour
Journal of Neurochemistry 125 (4) 532 (2013)

Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment

David J. G. Watson, Charles A. Marsden, Mark J. Millan and Kevin C. F. Fone
The International Journal of Neuropsychopharmacology 15 (04) 471 (2012)

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

Mark J. Millan, Yves Agid, Martin Brüne, et al.
Nature Reviews Drug Discovery 11 (2) 141 (2012)

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

S Miyamoto, N Miyake, L F Jarskog, W W Fleischhacker and J A Lieberman
Molecular Psychiatry 17 (12) 1206 (2012)

Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex

David JG Watson, Florence Loiseau, Manuela Ingallinesi, et al.
Neuropsychopharmacology 37 (3) 770 (2012)

Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice

Martin Egeland, Xiaoqun Zhang, Mark J. Millan, Elisabeth Mocaer and Per Svenningsson
Journal of Neurochemistry 123 (5) 811 (2012)

Influence of social isolation in the rat on serotonergic function and memory – Relevance to models of schizophrenia and the role  of 5-HT6 receptors

Charles A. Marsden, Madeleine V. King and Kevin C.F. Fone
Neuropharmacology 61 (3) 400 (2011)

Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist

Graham Searle, John D. Beaver, Robert A. Comley, et al.
Biological Psychiatry 68 (4) 392 (2010)

The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures

Mark J. Millan, Jerry J. Buccafusco, Florence Loiseau, et al.
The International Journal of Neuropsychopharmacology 13 (08) 1035 (2010)

Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders

Christian A. Heidbreder and Amy H. Newman
Annals of the New York Academy of Sciences 1187 (1) 4 (2010)

From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease

Mark J. Millan
Pharmacology & Therapeutics 128 (2) 229 (2010)

Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: Similar actions of D1 receptor agonists, but not of D2 antagonists

Florence Loiseau and Mark J. Millan
European Neuropsychopharmacology 19 (1) 23 (2009)

The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats

Xiao-Qing Peng, Charles R. Ashby, Krista Spiller, et al.
Neuropharmacology 56 (4) 752 (2009)

Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: Improvements of affinity and selectivity for D3 versus D2 receptors

Jean-Louis Peglion, Christophe Poitevin, Clotilde Mannoury La Cour, Delphine Dupuis and Mark J. Millan
Bioorganic & Medicinal Chemistry Letters 19 (8) 2133 (2009)

Dual- and Triple-Acting Agents for Treating Core and Co-morbid Symptoms of Major Depression: Novel Concepts, New Drugs

Mark J. Millan
Neurotherapeutics 6 (1) 53 (2009)